Repository logo
 
Publication

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

2022Journal article Open access
Simple item page
dc.contributor.authorMcCleary, NJ
dc.contributor.authorHarmsen, WS
dc.contributor.authorHaakenstad, El
dc.contributor.authorCleary, JM
dc.contributor.authorMeyerhardt, JA
dc.contributor.authorZalcberg, J
dc.contributor.authorAdams, R
dc.contributor.authorGrothey, A
dc.contributor.authorSobrero, AF
dc.contributor.authorVan Cutsem, E
dc.contributor.authorGoldberg, RM
dc.contributor.authorPeeters, M
dc.contributor.authorTabernero, J
dc.contributor.authorSeymour, M
dc.contributor.authorSaltz, LB
dc.contributor.authorGiantonio, BJ
dc.contributor.authorArnold, D
dc.contributor.authorRothenberg, ML
dc.contributor.authorKoopman, M
dc.contributor.authorSchmoll, HJ
dc.contributor.authorPitot, HC
dc.contributor.authorHoff, PM
dc.contributor.authorTebbutt, N
dc.contributor.authorMasi, G
dc.contributor.authorSouglakos, J
dc.contributor.authorBokemeyer, C
dc.contributor.authorHeinemann, V
dc.contributor.authorYoshino, T
dc.contributor.authorChibaudel, B
dc.contributor.authordeGramont, A
dc.contributor.authorShi, Q
dc.contributor.authorLichtman, SM
dc.date.issued2022
dc.description.abstractBackground: We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials. Methods: Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided. Results: Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively). Conclusions: Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJNCI Cancer Spectr . 2022 Mar 2;6(2):pkac014.pt_PT
dc.identifier.doi10.1093/jncics/pkac014pt_PT
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectNeoplasias do Colonpt_PT
dc.subjectNeoplasias do Rectopt_PT
dc.subjectColonic Neoplasmspt_PT
dc.subjectRectal Neoplasmspt_PT
dc.titleMetastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trialspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue2pt_PT
oaire.citation.titleJNCI Cancer Spectrumpt_PT
oaire.citation.volume6pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pkac014.pdf
Size:
1.76 MB
Format:
Adobe Portable Document Format
Download

Collections

ICO - Artigos